Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tetra Discovery Partners LLC

Capping PDE4 enzymes to treat memory loss, depression

This article was originally published in Start Up

Executive Summary

Mark Gurney, one of the scientists credited with discovering the gene for beta-secretase, was surprised and disappointed when beta-amyloid antibodies failed to help Alzheimer’s disease patients, but he believes he has found an approach that will work: a mechanistically novel way of selectively inhibiting specific forms of PDE4. This is a bold bet for his start-up Tetra Discovery Partners LLC to pursue, given how grievously many major drugmakers failed in earlier efforts to inhibit PDE4.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts